(Q35068048)

6 August 2017

1 reference

title

Management of chronic hepatitis B. (English)

1 reference

6 August 2017

1 reference

Hari S Conjeevaram

1

1 reference

PubMed ID

12591188

6 August 2017

Anna Suk-Fong Lok

series ordinal

2

1 reference

6 August 2017

1 January 2003

1 reference

6 August 2017

Journal of Hepatology

1 reference

6 August 2017

38 Suppl 1

1 reference

6 August 2017

S90-103

1 reference

Hepatitis B virus infection

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Management of hepatitis B: 2000--summary of a workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Hepatitis B e antigen and the risk of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Genetic variability in hepatitis B viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Clinical significance of hepatitis B virus genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Hepatitis B genotypes and the response to interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Clinical relevance of hepatitis B viral mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

The molecular basis of hepatitis B e antigen (HBeAg)-negative infections

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Interferon-alpha for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Long term effect of alpha interferon in children with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Long-term follow-up of chronic hepatitis B patients treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Repeated courses of alpha-interferon for treatment of chronic hepatitis type B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metanalysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

1 reference

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

New era of liver transplantation for hepatitis B: a 17-year single-center experience

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Hepatitis B viral genotypes and lamivudine resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax).

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900431-2

7 January 2021

10.1016/S0168-8278(02)00431-2

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12591188